Skip to main content
. 2023 Mar 28;41(18):2879–2886. doi: 10.1016/j.vaccine.2023.03.054

Fig 1.

Fig 1

Age and sex of patients who experienced at least one adverse event following immunization with the BNT162b2 and the mRNA-1273 COVID-19 vaccines.